evidence table

Pine Bark Blood Pressure Randomized Trial Evidence Table

Structured evidence table for Pine Bark Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Pine Bark Blood Pressure Randomized TrialAs population aging accelerates, identifying modifiable risk factors and preventive strategies for cognitive decline has become increasingly important.2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
Pine Bark Blood Pressure Randomized Trial4 5 5 6 7 8 9 10 11 10 Mild cognitive impairment (MCI) represents an intermediate stage between normal cognitive function and dementia [], and individuals with MCI have a significantly higher risk of progressing to dementia than cognitively normal individuals [].2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
Pine Bark Blood Pressure Randomized TrialLifestyle-related factors, including suboptimal dietary patterns, smoking, alcohol use, obesity, and physical inactivity, have been identified as modifiable risk factors for cognitive decline [].2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
Pine Bark Blood Pressure Randomized Trial1 2 3 Dementia is a major global health concern and a leading cause of disability and dependency among older adults worldwide [].2Hsiao Tse-Chia (2026)Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
Pine Bark Blood Pressure Randomized TrialResults Compared to control (247.5 ± 14.0 mmol/L⋅min), the iAUCglucose was significantly reduced with the 400 mg dose (211.8 ± 13.9 mmol/L⋅min, 14.4% reduction, and p = 0.037), but not with 50 mg dose (220.8 ± 14.2 mmol/L⋅min, 10.8% reduction, and p = 0.184).2Lim WXJ (2025)The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
Pine Bark Blood Pressure Randomized TrialCompared to control (9.1 ± 0.2 mmol/L), glucose peak value was significantly reduced with the 50 mg dose (8.6 ± 0.2 mmol/L, 5.5% reduction, and p = 0.016) but not with the 400 mg dose (8.7 ± 0.2 mmol/L, 4.4% reduction, and p = 0.093).2Lim WXJ (2025)The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
Pine Bark Blood Pressure Randomized TrialConclusions The New Zealand pine bark extract attenuated sucrose uptake with improved glycaemic responses, and may therefore be useful as a hypoglycaemic adjunct to the diet.2Lim WXJ (2025)The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
Pine Bark Blood Pressure Randomized TrialBackground The New Zealand pine bark has been demonstrated in vitro to inhibit digestive enzymes involved in carbohydrate digestion (alpha-amylase, alpha-glucosidase, and dipeptidyl-peptidase 4 (DPP-4)).2Lim WXJ (2025)The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
topicPine Bark Blood Pressure Randomized Trial
claimAs population aging accelerates, identifying modifiable risk factors and preventive strategies for cognitive decline has become increasingly important.
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Blood Pressure Randomized Trial
claim4 5 5 6 7 8 9 10 11 10 Mild cognitive impairment (MCI) represents an intermediate stage between normal cognitive function and dementia [], and individuals with MCI have a significantly higher risk of progressing to dementia than cognitively normal individuals [].
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Blood Pressure Randomized Trial
claimLifestyle-related factors, including suboptimal dietary patterns, smoking, alcohol use, obesity, and physical inactivity, have been identified as modifiable risk factors for cognitive decline [].
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Blood Pressure Randomized Trial
claim1 2 3 Dementia is a major global health concern and a leading cause of disability and dependency among older adults worldwide [].
evidence level2
citationHsiao Tse-Chia (2026)
sourceCombined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
topicPine Bark Blood Pressure Randomized Trial
claimResults Compared to control (247.5 ± 14.0 mmol/L⋅min), the iAUCglucose was significantly reduced with the 400 mg dose (211.8 ± 13.9 mmol/L⋅min, 14.4% reduction, and p = 0.037), but not with 50 mg dose (220.8 ± 14.2 mmol/L⋅min, 10.8% reduction, and p = 0.184).
evidence level2
citationLim WXJ (2025)
sourceThe Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
topicPine Bark Blood Pressure Randomized Trial
claimCompared to control (9.1 ± 0.2 mmol/L), glucose peak value was significantly reduced with the 50 mg dose (8.6 ± 0.2 mmol/L, 5.5% reduction, and p = 0.016) but not with the 400 mg dose (8.7 ± 0.2 mmol/L, 4.4% reduction, and p = 0.093).
evidence level2
citationLim WXJ (2025)
sourceThe Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
topicPine Bark Blood Pressure Randomized Trial
claimConclusions The New Zealand pine bark extract attenuated sucrose uptake with improved glycaemic responses, and may therefore be useful as a hypoglycaemic adjunct to the diet.
evidence level2
citationLim WXJ (2025)
sourceThe Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.
topicPine Bark Blood Pressure Randomized Trial
claimBackground The New Zealand pine bark has been demonstrated in vitro to inhibit digestive enzymes involved in carbohydrate digestion (alpha-amylase, alpha-glucosidase, and dipeptidyl-peptidase 4 (DPP-4)).
evidence level2
citationLim WXJ (2025)
sourceThe Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.

Learn next

Related evidence and supplement guides

GuidePine Bark Blood Pressure Randomized Trial: What the Evidence SaysPine Bark Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence...GuidePine Bark Blood Pressure Meta-analysis: What the Evidence SaysPine Bark Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence dat...GuideNicotinamide Blood Pressure Randomized Trial: What the Evidence SaysNicotinamide Blood Pressure Randomized Trial has 2 source documents in the current Migaku eviden...GuideChokeberry Blood Pressure Randomized Trial: What the Evidence SaysChokeberry Blood Pressure Randomized Trial has 2 source documents in the current Migaku evidence...AnswerDoes Pine Bark Blood Pressure Randomized Trial work?Pine Bark Blood Pressure Randomized Trial has evidence relevant to strength of evidence and what...AnswerIs Pine Bark Blood Pressure Randomized Trial safe?Pine Bark Blood Pressure Randomized Trial has evidence relevant to safety, limits, and clinician...AnswerWhat does the evidence say about Pine Bark Blood Pressure Randomized Trial?Pine Bark Blood Pressure Randomized Trial has evidence relevant to benefits, uncertainty, and pr...AnswerDoes Nicotinamide Blood Pressure Randomized Trial work?Nicotinamide Blood Pressure Randomized Trial has evidence relevant to strength of evidence and w...

Source documents

  1. Combined Fish Oil and Pine Bark Extract Supplementation Improves Short-Term Memory and the Antioxidant Status in Middle-Aged and Older Adults with Mild Cognitive Impairment: A Randomized Double-Blind, Parallel-Group Pilot Study
  2. The Hypoglycaemic Effects of the New Zealand Pine Bark Extract on Sucrose Uptake and Glycaemic Responses in Healthy Adults-A Single-Blind, Randomised, Placebo-Controlled, Crossover Trial.